Related Experiment Video
Updated: Nov 5, 2025
09:04
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
920
Immunotherapies targeting stimulatory pathways and beyond.
Julian A Marin-Acevedo1, ErinMarie O Kimbrough2, Rami Manochakian2
1Department of Hematology and Oncology, H. Lee Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, 33612, FL, USA.
Journal of Hematology & Oncology
|May 13, 2021
Summary
This review explores novel immunotherapies targeting T cell stimulatory pathways to enhance anti-tumor activity. It summarizes ongoing clinical trials, highlighting their potential to overcome tumor-induced immunosuppression.
Area of Science:
- Immunology
- Oncology
- Clinical Trials
Background:
- Co-stimulatory and co-inhibitory molecules regulate T cell function.
- Tumor cells evade immune surveillance via immunosuppression.
- Current immunotherapies (anti-CTLA-4, anti-PD-1/PD-L1) show efficacy in a subset of patients.
Purpose of the Study:
- To review novel immunotherapies targeting stimulatory pathways.
- To evaluate current phase I/II clinical trials in this area.
- To outline the advantages, limitations, and future directions of these novel therapies.
Main Methods:
- Literature review of current phase I/II clinical trials.
- Analysis of immunotherapies targeting T cell stimulatory pathways.
- Summary of clinical trial data on efficacy and safety.
Main Results:
- Emerging immunotherapies target stimulatory pathways for enhanced anti-tumor activity.
- Clinical trials are evaluating novel agents with potential benefits.
- Understanding mechanisms of action and resistance is crucial.
Conclusions:
- Targeting stimulatory pathways offers a promising avenue for cancer immunotherapy.
- Further research and clinical trials are needed to optimize treatment strategies.
- Combination therapies may enhance patient responses and overcome resistance.
Keywords:
CancerCo-stimulatory pathwayCytotoxic T lymphocytesImmune checkpointImmune evasionImmunotherapyTumor microenvironmentMore Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
801
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
801
02:57Targeted Cancer Therapies
8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.0K
01:30Cancer Vaccines
600
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
600
01:27Cytotoxic T Cells-mediated Immune Response
5.5K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
5.5K
02:49Cancer Therapies
8.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
02:38Mitogens and the Cell Cycle
7.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K